logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer Reveals Positive One Year Results In Phase 3 CRVO Program Of VEGF Trap-Eye

Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) announced that top-line results with VEGF Trap-Eye after one year of treatment in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion or CRVO confirm the primary endpoint results that were seen after 24 weeks from the two pivotal trials, GALILEO and COPERNICUS. The results are in line with earlier reported one-year results from the COPERNICUS study.

Based on the study results, Regeneron (REGN) has already submitted a supplemental Biologics License Application or sBLA in the U.S. and has been granted a FDA action date of September 23, 2012. Bayer HealthCare intends to file a marketing application with regulatory authorities in Europe in the 2012 second half. Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye.

The one-year GALILEO results demonstrated that the proportion of subjects that gained at least 15 letters of vision from baseline to week 52 was 60.2% of patients receiving VEGF Trap-Eye, versus 32.4% of patients receiving sham injections. On the other hand, the one-year COPERNICUS results showed that 55.3% of patients receiving VEGF Trap-Eye dosed monthly for 24 weeks, then on an as-needed basis over the next 28 weeks, gained at least 15 letters on an eye chart compared to 30.1% of patients who received sham injections for the first 24 weeks followed by VEGF Trap-Eye PRN from week 24 to week 52.

Also, the company added that the encouraging results of GALILEO and COPERNICUS for patients with central retinal vein occlusion show a durable improvement in visual acuity after one year of treatment with VEGF Trap-Eye. These data are being presented at the World Ophthalmology Congress in Abu Dhabi today.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Best Buy Co., Inc. (BBY) reported first-quarter non-GAAP earnings per share from continuing operations of $0.44, an increase of 19% from $0.37, a year ago. On average, 21 analysts polled by Thomson Reuters expected the company to report profit per share of $0.35 for the quarter. Analysts' estimates typically... Automotive parts retailer AutoZone, Inc. on Tuesday reported a 6 percent increase in profit for the third quarter from last year, reflecting growth in sales and higher inventory on new store openings. However, both revenue and earnings per share for the quarter missed analysts' expectations. Toll Brothers, Inc. (TOL), the nation's leading builder of luxury homes, reported second-quarter net income of $89.1 million, or $0.51 per share, compared to $67.9 million, or $0.37 per share, prior year. Pre-tax income increased to $140.4 million from $86.5 million. On average, 18 analysts polled by...
comments powered by Disqus
Follow RTT